晚期乳腺癌联合化疗的临床观察

目的 观察紫杉醇联合表阿霉素（TE方案）及诺维本联合表阿霉素（NE方案）治疗晚期乳腺癌的临床疗效和不良反应。方法 对120例晚期乳腺癌患者随机分为TE组58例和NE组62例，分别进行治疗观察。结果 TE组总有效率（65.5 %）和复治有效率（61.8 %）高于NE组（38.7 %和27.8 %），中位疾病进展时间长于NE组（P＜0.05）；两组初治有效率和中位生存期无显著差异（P＞0.05）；不良反应以骨髓抑制、胃肠反应和脱发为主，两组无显著差异性；NE组静脉炎、TE组关节肌肉酸痛的发生率相对高，但均可耐受。结论 紫杉醇联合表阿霉素和诺维本联合表阿霉素对晚期乳腺癌均有较好疗效，但TE组对复治患者疗效更好，可作为复治的晚期乳腺癌患者首选化疗方案。

The clinical observation of combined chemotherapy for advanced breast cancer

Objective To evaluate the efficacy and toxicity of paclitaxel and epirubicin (TE regimen) versus navelbine and epirubicin (NE regimen) in the treatment of advanced breast cancer. Methods A total of 120 patients with advanced breast cancer proved pathologyically were randomly divided into TE group (n=58) and NE group (n=62). Results TE regimen produced a higher response rate (RR) than NE regimen in the whole cases (65.5% and 38.7% respectively) and the retreatment cases (61.8% and 27.8% respectively) (P<0.05).The median time to progress (TP) in TE group was longer than that in NE group (P<0.05).However, there was no significant difference between two groups in the RR of the initial treatment and the median survival(P>0.05).The main toxicities were bone marrow depression, digestive reaction and alopecia, which were similar in two groups. Phlebitis was more common in NE group than in TE group, but articular and muscular soreness was more serious in TE group. All side effects were tolerable. Conclusion Both the two regimen are effective and well-tolerated in the treatment of advanced breast cancer. However, TE regimen is more effective in retreatment cases and could be considered as relevant regimen for retreated patients.